Lupin Announces Final FDA Approval of Generic Hyzaar® and Cozaar

Emirates PharmaAdvertisement

Pharma Major, Lupin Limited announced that its U.S subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has been granted final approval for the company’s generic versions of Merck’s antihypertensive agents *Hyzaar® (hydrochlorothiazide; losartan potassium) and *Cozaar® (losartan potassium) by the U.S. Food and Drug Administration.

The brand products had combined annual sales of approximately $1.6 billion in the United States, based on IMS sales data for the 12 months ended June 2010.

Emirates PharmaAdvertisement